History

Milestones

September – 2015

Company establishment in Jakarta, Indonesia

July – 2016

Factory ground breaking ceremony (building production facilities for lyophilized powder injection and liquid injection)

September – 2016

Starting sales & marketing activities for importation of oncology and immunosuppressant products from CKD, South Korea

December – 2017

Completion of manufacturing construction in Cikarang, Indonesia

September – 2018

Obtaining GMP (Good Manufacturing Practice) certificate from BPOM (Indonesian FDA)

February – 2019

Obtaining Halal certificate from MUI (Indonesian Council of Ulama) with excellent category

July – 2019

Grand opening ceremony and manufacture inauguration with Kemenkes (Indonesian MoH)

First launch of targeted oral oncology product, Leukivec

August – 2020

Obtaining TKDN (Level of Domestic Content ) from Kemenperin (Indonesian MoI)

January – 2021

Starting Local CMO (Contract Manufacturing Organization) business

March – 2021

Signing the contract of exportation with one MENA Country

October – 2021

First exportation shipment to one MENA Country

August 2022

Inspected by SFDA (Saudi Food and Drug Authority) for GMP Compliances

September – 2022

Obtaining BMP (Company Benefit Weight) from Kemenperin (Indonesian MOI)

Obtaining ISO 14001:2015 (Environmental Management System) from SIS (Syndicate of International System) Certifications

Progress of Cytotoxic injection registration in ASEAN and GCC countries

September – 2023

 Inspected by ANPP (National Agency for Pharmaceutical Products / Algerian FDA) for GMP Compliances

December – 2023

Moving our HQ location to Sudirman Street, central business district in Jakarta

October – 2024

Inspected by MFDS (Ministry of Food and Drug Safety / Korean FDA) for GMP Compliances

November – 2024

Obtaining ISO 45001:2018 (Occupational Health and Safety Management System) from SIS (Syndicate of International System) Certifications

Our Shareholder

Meet CKD OTTO Shareholders

Key partners who support our commitment to pharmaceutical innovation and advances in cancer treatment.

Scroll to Top